{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:23:43Z","timestamp":1790533423185,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00259-020-05015-2","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T22:03:20Z","timestamp":1598652200000},"page":"1144-1153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma"],"prefix":"10.1007","volume":"48","author":[{"given":"G.","family":"Manson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Herbaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Deau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bouteloup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Schiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maerevoet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stamatoullas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Antier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Charette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Poizeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dercle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"5015_CR1","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma. J Clin Oncol. 2017;35:2125\u201332 [Internet]. American Society of Clinical Oncology. [cited 2017 May 19]. Available from: http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2016.72.1316.","journal-title":"J Clin Oncol"},{"key":"5015_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36:1428\u201339 [Internet]. Available from: http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.76.0793.","journal-title":"J Clin Oncol"},{"key":"5015_CR3","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/annonc\/mdx341","volume":"28","author":"H Bek\u00f6z","year":"2017","unstructured":"Bek\u00f6z H, Karadurmu\u015f N, Payda\u015f S, T\u00fcrker A, Topta\u015f T, F\u0131ratl\u0131 Tu\u011flular T, et al. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Oncol. 2017;28:2496\u2013502 [Internet]. Available from: http:\/\/academic.oup.com\/annonc\/article\/doi\/10.1093\/annonc\/mdx341\/3903080\/Nivolumab-for-relapsed-or-refractory-Hodgkin.","journal-title":"Ann Oncol"},{"key":"5015_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","volume":"115","author":"G Manson","year":"2019","unstructured":"Manson G, Mear J, Herbaux C, Schiano J-M, Casasnovas O, Stamatoullas A, et al. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer. 2019;115:47\u201356 [Internet]. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919302394.","journal-title":"Eur J Cancer"},{"key":"5015_CR5","doi-asserted-by":"publisher","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087. Blood. 2019. https:\/\/doi.org\/10.1182\/blood.2019000324. [Internet]. Available from: http:\/\/www.bloodjournal.org\/lookup\/doi\/10.1182\/blood.2019000324.","DOI":"10.1182\/blood.2019000324"},{"key":"5015_CR6","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1182\/blood-2018-03-841262","volume":"131","author":"G Manson","year":"2018","unstructured":"Manson G, Herbaux C, Brice P, Bouabdallah K, Stamatoullas A, Schiano J-M, et al. Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. Blood. 2018;131:2856\u20139 [Internet]. Available from: http:\/\/www.bloodjournal.org\/lookup\/doi\/10.1182\/blood-2018-03-841262.","journal-title":"Blood"},{"key":"5015_CR7","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128:2489\u201396 [Internet]. American Society of Hematology. [cited 2019 mar 22]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27574190.","journal-title":"Blood"},{"key":"5015_CR8","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma [Internet]. J Clin Oncol. 2007:579\u201386. [cited 2018 Apr 3]. Available from: http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.09.2403."},{"key":"5015_CR9","unstructured":"Dercle L, Lu L, Schwartz LH, Qian M, Tejpar S, Eggleton P, et al. Radiomics response signature for identification of metastatic colorectal cancer sensitive to therapies targeting EGFR pathway. J Natl Cancer Inst. 2020. [Internet]. Oxford University Press (OUP). [cited 2020 Aug 11]; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32016387\/."},{"key":"5015_CR10","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-19-2942","volume":"26","author":"L Dercle","year":"2020","unstructured":"Dercle L, Dercle L, Dercle L, Fronheiser M, Lu L, Du S, et al. Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics. Clin Cancer Res. 2020;26:2151\u201362 [Internet]. American Association for Cancer Research Inc. [cited 2020 Aug 11]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32198149\/.","journal-title":"Clin Cancer Res"},{"key":"5015_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2967\/jnumed.119.232827","volume":"61","author":"A Chen","year":"2020","unstructured":"Chen A, Mokrane F-Z, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella J-M, et al. Early 18 F-FDG PET\/CT response predicts survival in relapsed or refractory hodgkin lymphoma treated with nivolumab. J Nucl Med. 2020;61:649\u201354. [Internet]. Available from: http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.119.232827.","journal-title":"J Nucl Med"},{"key":"5015_CR12","first-page":"192056","volume":"18","author":"F-Z Mokrane","year":"2020","unstructured":"Mokrane F-Z, Chen A, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella J-M, et al. Performance of CT compared with 18 F-FDG PET in predicting the efficacy of nivolumab in relapsed or refractory Hodgkin lymphoma. Radiology. 2020;18:192056 [Internet]. Available from: http:\/\/pubs.rsna.org\/doi\/10.1148\/radiol.2020192056.","journal-title":"Radiology"},{"key":"5015_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood.V73.1.47.47","volume":"73","author":"M Tubiana","year":"1989","unstructured":"Tubiana M, Henry-Amar M, Carde P, Burgers JMV, Hayat M, Van Der Schueren E, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin\u2019s disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989;73:47\u201356.","journal-title":"Blood."},{"key":"5015_CR14","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease. N Engl J Med. 1998;339:1506\u201314 [Internet]. Massachusetts Medical Society. [cited 2020 May 11]. Available from: http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJM199811193392104.","journal-title":"N Engl J Med"},{"key":"5015_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2217\/imt-2019-0066","volume":"11","author":"RD Nipp","year":"2019","unstructured":"Nipp RD, Gainor JF. A coming of age for immune checkpoint inhibitors in cancer. Immunotherapy. 2019;11:647\u201350 [Internet]. Available from: https:\/\/www.futuremedicine.com\/doi\/10.2217\/imt-2019-0066.","journal-title":"Immunotherapy"},{"key":"5015_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ctrv.2017.08.003","volume":"60","author":"R Ferrara","year":"2017","unstructured":"Ferrara R, Mezquita L, Auclin E, Chaput N, Besse B. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter? Cancer Treat Rev. 2017;60:60\u20138 [Internet]. W.B. Saunders. [cited 2018 Jan 16]. Available from: http:\/\/www.sciencedirect.com.gate2.inist.fr\/science\/article\/pii\/S0305737217301263?via%3Dihub.","journal-title":"Cancer Treat Rev"},{"key":"5015_CR17","doi-asserted-by":"publisher","unstructured":"Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, et al. Efficacy of immune checkpoint inhibitors and age in cancer patients. Immunotherapy. 2020. https:\/\/doi.org\/10.2217\/imt-2019-0124. [Internet]. Available from: https:\/\/www.futuremedicine.com\/doi\/10.2217\/imt-2019-0124.","DOI":"10.2217\/imt-2019-0124"},{"key":"5015_CR18","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","volume":"129","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales M-A, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma. Blood. 2017;129:1380\u20138 [Internet]. [cited 2017 mar 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28073785.","journal-title":"Blood"},{"key":"5015_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2967\/jnumed.117.193011","volume":"59","author":"L Dercle","year":"2018","unstructured":"Dercle L, Seban R-D, Lazarovici J, Schwartz LH, Houot R, Ammari S, et al. 18 F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti\u2013programmed death 1 immune checkpoint inhibitor. J Nucl Med. 2018;59:15\u201324 [Internet]. Available from: http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.117.193011.","journal-title":"J Nucl Med"},{"key":"5015_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejca.2017.12.015","volume":"91","author":"L Dercle","year":"2018","unstructured":"Dercle L, Ammari S, Seban RD, Schwartz LH, Houot R, Labaied N, et al. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. Eur J Cancer. 2018;91:136\u201344.","journal-title":"Eur J Cancer"},{"key":"5015_CR21","doi-asserted-by":"crossref","unstructured":"Dercle L, Mokrane FZ, Schiano de Colella JM, Stamatoullas A, Morschhauser F, Brice P, et al. Unconventional immune-related phenomena observed using 18F-FDG PET\/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies. Eur J Nucl Med Mol Imaging. 2019.","DOI":"10.1007\/s00259-019-04310-x"}],"updated-by":[{"DOI":"10.1007\/s00259-021-05321-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000}}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05015-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-05015-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05015-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T23:31:18Z","timestamp":1630107078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-05015-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5015"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-05015-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00259-021-05321-3","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00259-021-05321-3","URL":"https:\/\/doi.org\/10.1007\/s00259-021-05321-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.M. and P.B. have received consulting fees and\/or honoraria from Bristol-Myers Squibb. M.G.S received research grant form Gilead Sciences, and was consultant for Abbvie, Gilead Sciences, Janssen Cilag, Roche. E.N-V. received consulting fees from Sanofi. A.S. has received consulting fees from Takeda and Celgene. C.C.-S. received honoraria for speaker engagements from Bristol Myers Squibb, Merck Sharp & Dohme, Amgen, Janssen Oncology, Astra-Zeneca; provided consultancy to Boehringer Ingelheim, Sanofi, ADC Therapeutics; and received scientific advisory fee from Servier, Novartis, Roche, ADC Therapeutics; and received research funding from Rhizen Pharmaceuticals. RH received honoraria from Bristol-Myers Squibb, MSD, Gilead, Kite, Roche, Novartis, Janssen, and Celgene. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}